We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,124

Board’s Failure to Adhere to Best Practices in Drug Clinical Trial Does Not Excuse Stockholder Demand as Futile
  • K&L Gates
  • USA
  • March 26 2018

In Wilkin v. Narachi, et al., and Orexigen Therapeutics, Inc., Civil Action No. 12412-VCMR (Del. Ch. February 28, 2018), the Delaware Court of


Hong Kong Announces Groundbreaking New Rules for Dual-Class Share, High-Tech and Biotech Company Listings
  • Skadden Arps Slate Meagher & Flom LLP
  • Hong Kong
  • February 26 2018

After publishing the “New Board Concept Paper Conclusions” in December 2017, the Stock Exchange of Hong Kong Limited (the Exchange) issued on 23


Delhi High Court upholds foreign award in favour of daiichi (except qua minor respondents)
  • Khaitan & Co
  • Singapore, India
  • February 6 2018

By a judgment delivered on 31 January 2018, the Delhi High Court has held that the award passed in favour of Daiichi Sankyo Company Ltd. (the


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon


Global Privacy & Cybersecurity Update Vol. 15
  • Jones Day
  • USA, European Union, Global
  • September 13 2017

On June 19, the Federal Trade Commission ("FTC") submitted comments to a working group organized by the Department of Commerce's National


Dietary Supplement & Cosmetics Legal Bulletin: March 2017
  • Shook Hardy & Bacon LLP
  • USA
  • March 31 2017

FDA Warning Letters on the Rise. Nearly 30 warning letters were issued by the U.S. Food and Drug Administration (FDA) regarding


Prime Therapeutics Notice of Audit or Termination of Agreement - What You Need to Know
  • FisherBroyles LLP
  • USA
  • January 30 2017

It has come to our attention that Prime Therapeutics (Prime), a Pharmacy Benefit Manager (PBM) that maintains contractual agreements with many


Regulatory Concerns Around Big Data, Artificial Intelligence and the IoT
  • Manatt Phelps & Phillips LLP
  • USA
  • January 23 2017

Data is everywhere. By some estimates, 90 of the world's data has been created in the last two years. This deluge is only going to intensify as the


"Key Takeaways: Fourth Annual Seminar for Pharmaceutical, Biotechnology and Medical Device Companies"
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • October 24 2016

On October 5, 2016, Skadden hosted its Fourth Annual Seminar for Pharmaceutical, Biotechnology and Medical Device Companies. The seminar focused on


Advertising Litigation Report: Vol. I, No. 3
  • Kramer Levin Naftalis & Frankel LLP
  • USA
  • August 9 2016

In a dispute between rival pharmaceutical manufacturers, the Second Circuit affirmed summary judgment for defendant Acorda Therapeutics, adopting the